1: Reynoso-Moreno I, Tietz S, Vallini E, Engelhardt B, Gertsch J, Chicca A. Selective Endocannabinoid Reuptake Inhibitor WOBE437 Reduces Disease Progression in a Mouse Model of Multiple Sclerosis. ACS Pharmacol Transl Sci. 2021 Mar 26;4(2):765-779. doi: 10.1021/acsptsci.0c00214. PMID: 33860200; PMCID: PMC8033750.
2: Mäder P, Bartholomäus R, Nicolussi S, Baumann A, Weis M, Chicca A, Rau M, Simão AC, Gertsch J, Altmann KH. Synthesis and Biological Evaluation of Endocannabinoid Uptake Inhibitors Derived from WOBE437. ChemMedChem. 2021 Jan 8;16(1):145-154. doi: 10.1002/cmdc.202000153. Epub 2020 May 26. PMID: 32369259.
3: Reynoso-Moreno I, Chicca A, Flores-Soto ME, Viveros-Paredes JM, Gertsch J. The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable and Exerts Indirect Polypharmacological Effects via Different Endocannabinoid Receptors. Front Mol Neurosci. 2018 May 28;11:180. doi: 10.3389/fnmol.2018.00180. PMID: 29910713; PMCID: PMC5992379.
4: Gagestein B, Stevens AF, Fazio D, Florea BI, van der Wel T, Bakker AT, Fezza F, Dulk HD, Overkleeft HS, Maccarrone M, van der Stelt M. Chemical Proteomics Reveals Off-Targets of the Anandamide Reuptake Inhibitor WOBE437. ACS Chem Biol. 2022 May 20;17(5):1174-1183. doi: 10.1021/acschembio.2c00122. Epub 2022 Apr 28. PMID: 35482948; PMCID: PMC9127799.
5: Chicca A, Nicolussi S, Bartholomäus R, Blunder M, Aparisi Rey A, Petrucci V, Reynoso-Moreno IDC, Viveros-Paredes JM, Dalghi Gens M, Lutz B, Schiöth HB, Soeberdt M, Abels C, Charles RP, Altmann KH, Gertsch J. Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake. Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):E5006-E5015. doi: 10.1073/pnas.1704065114. Epub 2017 Jun 5. PMID: 28584105; PMCID: PMC5488949.
6: Miller S, Daily L, Dharla V, Gertsch J, Malamas MS, Ojima I, Kaczocha M, Ogasawara D, Straiker A. Endocannabinoid metabolism and transport as targets to regulate intraocular pressure. Exp Eye Res. 2020 Dec;201:108266. doi: 10.1016/j.exer.2020.108266. Epub 2020 Sep 23. PMID: 32979397; PMCID: PMC8054225.